See more : Valartis Group AG (0RPP.L) Income Statement Analysis – Financial Results
Complete financial analysis of Silence Therapeutics plc (SLN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Silence Therapeutics plc, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Stora Enso Oyj (SEOAY) Income Statement Analysis – Financial Results
- Woodward, Inc. (WWD) Income Statement Analysis – Financial Results
- Wuxi Xuelang Environmental Technology Co., Ltd. (300385.SZ) Income Statement Analysis – Financial Results
- Encres Dubuit (ALDUB.PA) Income Statement Analysis – Financial Results
- Etihad Etisalat Company (7020.SR) Income Statement Analysis – Financial Results
Silence Therapeutics plc (SLN)
About Silence Therapeutics plc
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.38M | 17.50M | 12.42M | 5.48M | 244.00K | 0.00 | 16.00K | 770.00K | 0.00 | 15.00K | 117.00K | 163.00K | 694.00K | 2.37M | 1.72M | 2.21M | 4.05M | 1.95M | 509.00K | 159.00K | 1.34M | 1.15M | 138.00K | 959.00K | 1.37M | 210.00K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 10.32M | 10.88M | 7.46M | 3.76M | 0.00 | 9.74M | 7.94M | 8.71M | 7.11M | 8.88M | 5.65M | 3.38M | 3.36M | 5.82M | 5.07M | 6.71M | 4.84M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 15.06M | 6.62M | 4.96M | 1.72M | 244.00K | -9.74M | -7.93M | -7.94M | -7.11M | -8.87M | -5.53M | -3.22M | -2.67M | -3.46M | -3.35M | -4.50M | -796.00K | 1.95M | 509.00K | 159.00K | 1.34M | 1.15M | 138.00K | 959.00K | 1.37M | 210.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 59.34% | 37.83% | 39.94% | 31.34% | 100.00% | 0.00% | -49,543.75% | -1,031.30% | 0.00% | -59,126.67% | -4,727.35% | -1,972.39% | -384.29% | -146.03% | -194.43% | -203.85% | -19.67% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 44.03M | 35.61M | 30.77M | 20.21M | 13.34M | 9.74M | 7.94M | 8.71M | 7.11M | 8.88M | 5.65M | 3.38M | 3.36M | 5.82M | 5.07M | 6.71M | 4.84M | 3.19M | 1.66M | 1.70M | 3.01M | 2.46M | 2.49M | 3.00M | 3.05M | 1.68M | 1.83M | 986.00K | 790.00K |
| General & Administrative | 20.64M | 19.61M | 20.01M | 13.98M | 9.64M | 10.83M | 6.46M | 3.97M | 2.66M | 3.26M | 3.54M | 2.61M | 2.65M | 5.13M | 3.19M | 3.29M | 4.99M | 3.03M | 2.75M | 1.83M | 1.01M | 700.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 20.64M | 19.61M | 20.01M | 13.98M | 9.64M | 10.83M | 6.46M | 3.97M | 2.66M | 3.26M | 3.54M | 2.61M | 2.65M | 5.13M | 3.19M | 3.29M | 4.99M | 3.03M | 2.75M | 1.83M | 1.01M | 700.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 0.00 | 0.00 | 0.00 | 3.37M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -269.00K | 7.00K | -112.00K | -20.00K | 72.00K | -154.00K | -21.00K | 56.00K | -1.00K | -216.00K | -287.00K | 673.00K | 693.00K | 503.00K | 429.00K | 329.00K | 258.00K | 143.00K |
| Operating Expenses | 64.66M | 55.21M | 50.77M | 37.56M | 22.98M | 20.57M | 14.41M | 12.68M | 9.77M | 12.14M | 9.19M | 5.99M | 2.65M | 5.13M | 4.18M | 3.29M | 4.84M | 6.21M | 4.40M | 3.53M | 4.02M | 3.16M | 3.17M | 3.69M | 3.55M | 2.11M | 2.16M | 1.24M | 933.00K |
| Cost & Expenses | 74.98M | 66.09M | 58.23M | 41.33M | 22.98M | 20.57M | 14.41M | 12.68M | 9.77M | 12.14M | 9.19M | 5.99M | 6.01M | 10.95M | 9.26M | 10.00M | 9.68M | 6.21M | 4.40M | 3.53M | 4.02M | 3.16M | 3.17M | 3.69M | 3.55M | 2.11M | 2.16M | 1.24M | 933.00K |
| Interest Income | 1.45M | 226.00K | 10.00K | 129.00K | 27.00K | 39.00K | 206.00K | 1.54M | 175.00K | 147.00K | 70.00K | 18.00K | 56.00K | 95.00K | 46.00K | 357.00K | 544.00K | 348.00K | 264.00K | 133.00K | 216.00K | 317.00K | 522.00K | 505.00K | 163.00K | 324.00K | 398.00K | 279.00K | 59.00K |
| Interest Expense | 34.00K | 47.00K | 8.00K | 323.00K | 163.00K | 0.00 | 15.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 13.00K | 63.00K | 0.00 | -31.00K | 0.00 | 20.00K | 1.00K | 71.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -398.00K | -279.00K | -59.00K |
| Depreciation & Amortization | 498.00K | 482.00K | 427.00K | 496.00K | 482.00K | 399.00K | 433.00K | 310.00K | 182.00K | 332.00K | 297.00K | 252.00K | 305.00K | 323.00K | 371.00K | 423.00K | 318.00K | 353.00K | 216.00K | 38.00K | 44.00K | 56.00K | 42.00K | 29.00K | 6.00K | 36.00K | 34.00K | 34.00K | 1.00K |
| EBITDA | -49.78M | -47.89M | -45.42M | -35.53M | -22.36M | -20.17M | -3.33M | -11.60M | -9.59M | -11.80M | -8.78M | -5.31M | -5.42M | -8.17M | -7.12M | -7.44M | -5.32M | -3.59M | -3.42M | -3.20M | -2.63M | -1.95M | -2.99M | -2.71M | -2.17M | -1.87M | -2.13M | -1.21M | -932.00K |
| EBITDA Ratio | -196.17% | -273.61% | -365.50% | -642.85% | -9,108.61% | 0.00% | -208,962.50% | -1,505.97% | 0.00% | -78,633.33% | -7,500.00% | -3,409.82% | -713.69% | -345.31% | -413.06% | -317.43% | -117.91% | -183.10% | -669.94% | -2,010.06% | -179.54% | -143.09% | -2,163.04% | -282.17% | -158.61% | -889.05% | 0.00% | 0.00% | 0.00% |
| Operating Income | -49.60M | -48.59M | -45.81M | -35.85M | -22.73M | -20.57M | -14.39M | -11.91M | -9.77M | -12.13M | -9.07M | -26.31M | -5.79M | -8.66M | -7.55M | -7.79M | -5.79M | -4.27M | -3.90M | -3.37M | -2.67M | -2.01M | -3.03M | -2.74M | -2.18M | -1.90M | -2.16M | -1.24M | -933.00K |
| Operating Income Ratio | -195.48% | -277.66% | -369.02% | -654.26% | -9,317.21% | 0.00% | -89,943.75% | -1,546.23% | 0.00% | -80,846.67% | -7,753.85% | -16,143.56% | -833.72% | -365.93% | -438.42% | -352.74% | -143.02% | -219.21% | -765.82% | -2,118.24% | -198.88% | -174.20% | -2,193.48% | -285.19% | -159.05% | -906.19% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -706.00K | 1.23M | -42.00K | -194.00K | -136.00K | 45.00K | 10.62M | 1.54M | 340.00K | 147.00K | 70.00K | -20.46M | 49.00K | -137.00K | 46.00K | 357.00K | 544.00K | 328.00K | 263.00K | 62.00K | 216.00K | 302.00K | 479.00K | 505.00K | 163.00K | 324.00K | 398.00K | 279.00K | 59.00K |
| Income Before Tax | -50.31M | -47.37M | -45.86M | -36.04M | -22.87M | -20.53M | -3.78M | -10.36M | -9.43M | -11.98M | -9.00M | -26.28M | -5.74M | -8.80M | -7.51M | -7.44M | -5.24M | -3.94M | -3.64M | -3.31M | -2.46M | -1.70M | -2.55M | -2.23M | -2.02M | -1.58M | -1.76M | -965.00K | -874.00K |
| Income Before Tax Ratio | -198.27% | -270.66% | -369.36% | -657.80% | -9,372.95% | 0.00% | -23,593.75% | -1,345.71% | 0.00% | -79,866.67% | -7,694.02% | -16,125.15% | -826.66% | -371.72% | -435.75% | -336.58% | -129.58% | -202.36% | -714.15% | -2,079.25% | -182.81% | -147.96% | -1,846.38% | -232.53% | -147.15% | -751.90% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -7.04M | -6.88M | -6.45M | -3.49M | -3.29M | -2.12M | -2.16M | -1.92M | -2.78M | -892.00K | -70.00K | -30.00K | -49.00K | 137.00K | -37.00K | -357.00K | -136.00K | -114.00K | -50.00K | -350.00K | -177.00K | -220.00K | -354.00K | -286.00K | 124.00K | -324.00K | -398.00K | -279.00K | -59.00K |
| Net Income | -43.27M | -40.49M | -39.41M | -32.55M | -19.58M | -18.41M | -1.62M | -8.44M | -6.65M | -11.09M | -9.00M | -26.28M | -5.74M | -8.80M | -7.47M | -7.44M | -5.11M | -3.83M | -3.59M | -2.96M | -2.28M | -1.48M | -2.19M | -1.94M | -2.14M | -1.58M | -1.76M | -965.00K | -874.00K |
| Net Income Ratio | -170.51% | -231.35% | -317.44% | -594.03% | -8,025.41% | 0.00% | -10,112.50% | -1,096.10% | 0.00% | -73,920.00% | -7,694.02% | -16,125.15% | -826.66% | -371.72% | -433.60% | -336.58% | -126.22% | -196.51% | -704.32% | -1,859.12% | -169.64% | -128.84% | -1,589.86% | -202.71% | -156.20% | -751.90% | 0.00% | 0.00% | 0.00% |
| EPS | -1.17 | -1.26 | -1.33 | -1.19 | -0.78 | -0.79 | -0.07 | -0.36 | -0.31 | -0.66 | -0.61 | -4.11 | -1.84 | -4.74 | -8.32 | -9.30 | -6.59 | -6.03 | -8.83 | -18.57 | -14.33 | -9.32 | -13.79 | -12.77 | -15.59 | -12.00 | -13.68 | -7.59 | -7.95 |
| EPS Diluted | -1.17 | -1.26 | -1.33 | -1.19 | -0.78 | -0.79 | -0.07 | -0.36 | -0.31 | -0.66 | -0.61 | -4.11 | -1.84 | -4.74 | -8.32 | -9.30 | -6.59 | -6.03 | -8.83 | -18.57 | -14.33 | -9.32 | -13.79 | -12.77 | -15.59 | -12.00 | -13.68 | -7.59 | -7.95 |
| Weighted Avg Shares Out | 37.09M | 32.19M | 29.65M | 27.26M | 25.04M | 23.44M | 23.31M | 23.27M | 21.34M | 16.81M | 14.64M | 6.39M | 3.11M | 1.86M | 897.60K | 799.24K | 775.31K | 634.26K | 405.84K | 159.15K | 159.07K | 159.07K | 159.07K | 152.23K | 137.25K | 131.57K | 128.69K | 127.20K | 109.93K |
| Weighted Avg Shares Out (Dil) | 37.09M | 32.19M | 29.65M | 27.26M | 25.04M | 23.44M | 23.31M | 23.27M | 21.34M | 16.81M | 14.64M | 6.39M | 3.11M | 1.86M | 897.60K | 799.24K | 775.31K | 634.26K | 405.84K | 159.15K | 159.07K | 159.07K | 159.07K | 152.23K | 137.25K | 131.57K | 128.69K | 127.20K | 109.93K |
Silence Therapeutics Provides SLN360 and SLN124 Clinical Program Updates
LONDON--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today provided the following SLN360 and SLN124 program updates during a presentation...
Silence Therapeutics Provides SLN360 and SLN124 Clinical Program Updates
LONDON--( BUSINESS WIRE )--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today provided the following SLN360 and SLN124 program updates during...
Silence Therapeutics PLC Sponsored ADR (SLN) Upgraded to Strong Buy: What Does It Mean for the Stock?
Silence Therapeutics PLC Sponsored ADR (SLN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Silence Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
LONDON--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that Craig Tooman, President and Chief Executive Officer of Silence,...
Silence Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
LONDON--( BUSINESS WIRE )--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced that Craig Tooman, President and Chief Executive Officer...
Silence Therapeutics: Excellent Data In A Cardiovascular Indication
SLN is a gene silencing therapy developer. SLN produced excellent data from its lead candidate.
Silence Therapeutics Reports Third Quarter 2022 Results
LONDON--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today reported its financial results for the third quarter ended September 30,...
Silence Therapeutics Reports Third Quarter 2022 Results
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today reported its financial results for the third quarter ended...
Silence Therapeutics to Present at Jefferies London Healthcare Conference
LONDON--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that Craig Tooman, President and Chief Executive Officer of Silence,...
Silence Therapeutics Presents New Analysis from SLN360 Phase 1 Single Dose Study in High Lipoprotein(a) at the American Heart Association (AHA) 2022 Annual Meeting
LONDON--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today presented data from an analysis of its APOLLO phase 1 single...
Source: https://incomestatements.info
Category: Stock Reports